In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mind The Maturity Gap: Medtechs Must Improve Digital And Omnichannel Uptake

Executive Summary

Boston Consulting Group began writing the third iteration of its report on next-generation commercial models to meet evolving medtech customer needs before COVID struck. But it findings and recommendations were even more relevant once the report – dubbed Milkman 3.0  ̶  was finally released in spring 2021, when learnings from the pandemic were being factored in by the medtech industry.

You may also be interested in...



Medtechs Told: Change Commercial Models Or Be Left Behind

Medical device companies working on the global stage are undergoing price and innovation productivity pressures just at the time that the markets are demanding a different type of service delivery from their suppliers. Smart manufacturers are reacting positively, with new commercial models, but they remain the exception to the rule, says the Boston Consulting Group, which is soon to release the second edition of its commercial benchmarking initiative.

Seven Trending Technologies On The Cusp Of Mainstream Uptake

At HIMSS22, NEO.Life’s Jane Metcalfe identified seven trending technologies that are set to move from the fringes of medicine to the center of attention.

Regulation, Digitization Mulled As Swiss Medtechs Look To An ‘EU+’ Vision For The Future

With Switzerland now operating as a third country to the EU, Swiss-based medtech manufacturers are keen to maximize their inherent advantages and build a basis for future growth.

Topics

UsernamePublicRestriction

Register

IV124936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel